PSTI - プルリステム・セラピュ―ティクス (Pluristem Therapeutics Inc.)

PSTIのニュース

   Pluristem''s PLX-R18 Shows Meaningful Advantage Over Other Treatments In Transplant Patients  2022/03/23 16:35:04 Benzinga
Pluristem Therapeutics Inc (NASDAQ: PSTI ) announced final results from its hematology Phase 1 study of intramuscular injections of PLX-R18 in subjects with incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT). Data collated 12 months post-treatment with PLX-R18 demonstrate that PLX-R18 was well-tolerated with … Full story available on Benzinga.com
   Pluristem PLX-R18 shows promise in blood cell recovery in cell transplant patients in trial  2022/03/23 15:59:38 Seeking Alpha
Pluristem Therapeutics (PSTI) reported final results from a phase 1 trial of intramuscular injections of PLX-R18 in patients with incomplete hematopoietic recovery following…
   PSTI, BLRX and BBIG among pre-market gainers  2022/01/18 13:18:34 Seeking Alpha
Mainz Biomed (MYNZ) +14%. Vinco Ventures (BBIG) +13%. Digital World Acquisition (DWACW) +11%. Pluristem Therapeutics (PSTI) +10%
   Pluristem Therapeutics Inc Shares Close the Day 10.3% Higher - Daily Wrap  2022/01/16 12:57:46 Kwhen Finance
Pluristem Therapeutics Inc (PSTI) shares closed today 10.3% higher than it did at the end of yesterday. The stock is currently up 32.2% year-to-date, down 76.0% over the past 12 months, and down 87.6% over the past five years. Today, the Dow Jones Industrial Average fell 0.6%, and the S&P 500 rose 0.0%. Trading Activity Shares traded as high as $2.04 and as low as $1.65 this week.Shares closed 77.6% below its 52-week high and 41.9% above its 52-week low.Trading volume this week was 96.1% lower than the 10-day average and 88.5% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -525.5% The company's stock price performance over the past 12 months lags the peer average by 130.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Thinking about buying stock in Pluristem Therapeutics, DiDi Global, Robinhood Markets, Bitfarms, or Adamis Pharmaceuticals?  2022/01/10 15:55:00 Benzinga
NEW YORK , Jan. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PSTI, DIDI, HOOD, BITF, and ADMP. Full story available on Benzinga.com
   Pluristem''s PLX-R18 Shows Meaningful Advantage Over Other Treatments In Transplant Patients  2022/03/23 16:35:04 Benzinga
Pluristem Therapeutics Inc (NASDAQ: PSTI ) announced final results from its hematology Phase 1 study of intramuscular injections of PLX-R18 in subjects with incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT). Data collated 12 months post-treatment with PLX-R18 demonstrate that PLX-R18 was well-tolerated with … Full story available on Benzinga.com
   Pluristem PLX-R18 shows promise in blood cell recovery in cell transplant patients in trial  2022/03/23 15:59:38 Seeking Alpha
Pluristem Therapeutics (PSTI) reported final results from a phase 1 trial of intramuscular injections of PLX-R18 in patients with incomplete hematopoietic recovery following…
   PSTI, BLRX and BBIG among pre-market gainers  2022/01/18 13:18:34 Seeking Alpha
Mainz Biomed (MYNZ) +14%. Vinco Ventures (BBIG) +13%. Digital World Acquisition (DWACW) +11%. Pluristem Therapeutics (PSTI) +10%
   Pluristem Therapeutics Inc Shares Close the Day 10.3% Higher - Daily Wrap  2022/01/16 12:57:46 Kwhen Finance
Pluristem Therapeutics Inc (PSTI) shares closed today 10.3% higher than it did at the end of yesterday. The stock is currently up 32.2% year-to-date, down 76.0% over the past 12 months, and down 87.6% over the past five years. Today, the Dow Jones Industrial Average fell 0.6%, and the S&P 500 rose 0.0%. Trading Activity Shares traded as high as $2.04 and as low as $1.65 this week.Shares closed 77.6% below its 52-week high and 41.9% above its 52-week low.Trading volume this week was 96.1% lower than the 10-day average and 88.5% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -525.5% The company's stock price performance over the past 12 months lags the peer average by 130.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Thinking about buying stock in Pluristem Therapeutics, DiDi Global, Robinhood Markets, Bitfarms, or Adamis Pharmaceuticals?  2022/01/10 15:55:00 Benzinga
NEW YORK , Jan. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PSTI, DIDI, HOOD, BITF, and ADMP. Full story available on Benzinga.com
   PSTI, BLRX and BBIG among pre-market gainers  2022/01/18 13:18:34 Seeking Alpha
Mainz Biomed (MYNZ) +14%. Vinco Ventures (BBIG) +13%. Digital World Acquisition (DWACW) +11%. Pluristem Therapeutics (PSTI) +10%
   Pluristem Therapeutics Inc Shares Close the Day 10.3% Higher - Daily Wrap  2022/01/16 12:57:46 Kwhen Finance
Pluristem Therapeutics Inc (PSTI) shares closed today 10.3% higher than it did at the end of yesterday. The stock is currently up 32.2% year-to-date, down 76.0% over the past 12 months, and down 87.6% over the past five years. Today, the Dow Jones Industrial Average fell 0.6%, and the S&P 500 rose 0.0%. Trading Activity Shares traded as high as $2.04 and as low as $1.65 this week.Shares closed 77.6% below its 52-week high and 41.9% above its 52-week low.Trading volume this week was 96.1% lower than the 10-day average and 88.5% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -525.5% The company's stock price performance over the past 12 months lags the peer average by 130.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Thinking about buying stock in Pluristem Therapeutics, DiDi Global, Robinhood Markets, Bitfarms, or Adamis Pharmaceuticals?  2022/01/10 15:55:00 Benzinga
NEW YORK , Jan. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PSTI, DIDI, HOOD, BITF, and ADMP. Full story available on Benzinga.com
   Biotech Pluristem, Israel-Based Tnuva Collaborate On Cultured Food Platform  2022/01/10 11:26:32 Benzinga
Pluristem Therapeutics Inc (NASDAQ: PSTI ) and Tnuva Group have collaborated to develop, manufacture and commercialize cultured cell-based products for the food industry. Tnuva Group is the largest food producer in Israel and the Israeli player in the field of alternative dairy and protein products. The collaboration started with the incorporation of a new company (NewCo) that will receive exclusive, global, royalty-bearing licensing rights to use Pluristem''s Full story available on Benzinga.com
   Pluristem jumps on collaboration with Tnuva to develop cultured cell-based food products  2022/01/10 10:28:43 Seeking Alpha
Pluristem Therapeutics (PSTI) and Tnuva Group, Israel’s largest food producer, announce the launch of an innovative collaboration to develop, manufacture and commercialize…

calendar